GSE38428   Details

GSE Accession GSE38428
Title Expression data from primary mouse Emu-myc B-cell lymphoma
Submission Date 6/3/12
Last Update Date 1/1/14
Pubmed ID
Experiment Type Expression profiling by array
Contributor Clemens,A,Schmitt; Julia Kase; Michael Hummel; Dido Lenze; Jan,R,Dörr; Maja Milanovic
Contact Name
Contact E-mail
Organization Name
Country
Organism
Organism ID
Organism Synonym
Summary We are interested in genetic programs and mutations which impact on tumor development and sensitivity to anticancer therapies. Utilizing Emu-myc transgenic mice, which spontaneously develop aggressive B-cell lymphomas, we aimed here to study the effects of drug responses in vivo, in particular genetic and biochemical components presented a priori in therapy-naive tumor cells, which determine the susceptibility of lymphoma cells to respond to standard chemotherapeutic drugs.; We used global gene expression profiling by microarrays to gain insight into the molecular program underlying the chemotherapy response potential in primary Emu-myc transgenic B-cell lymphomas.
Overall Design Immunocompetent recipient mice, transplanted with an aliquot of primary lymphoma cells explated from transgenic Emu-myc mice, were exposed to a single dose of Cyclophosphamide (CTX), a standard component of chemotherapeutic regimens used to treat human B-cell lymphomas. After obtaining long-term therapy response data in mice, therapy-naive aliquots of these same lymphomas were used for generating global expression profiles. This submission includes the therapy-naive lymphoma samples.
Platform ID
Timepoint Count 0
Timepoints
Disease
Disease ID